Psoriasis is a chronic inflammatory skin condition that has a fairly wide range of clinical presentations. Plaque psoriasis, which is the most common manifestation of psoriasis, is located on one end of the spectrum, dominated by adaptive immune responses, whereas the rarer pustular psoriasis lies on the opposite end, dominated by innate and autoinflammatory immune responses. In recent years, genetic studies have identified six genetic variants that predispose to pustular psoriasis, and these have highlighted the role of IL-36 cytokines as central to pustular psoriasis pathogenesis. In this review, we discuss the presentation and clinical subtypes of pustular psoriasis, contribution of genetic predisposing variants, critical role of the IL-36 family of cytokines in disease pathophysiology, and treatment perspectives for pustular psoriasis. We further outline the application of appropriate mouse models for the study of pustular psoriasis and address the outstanding questions and issues related to our understanding of the mechanisms involved in pustular psoriasis.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Sarac, G., Koca, T. T. & Baglan, T. A brief summary of clinical types of psoriasis. North Clin. Istanb. 3, 79–82 (2016).
Rendon, A. & Schakel, K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20, 1475 (2019).
Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N. Engl. J. Med. 361, 496–509 (2009).
Gudjonsson, J. E. & Elder, J. T. Psoriasis: epidemiology. Clin. Dermatol. 25, 535–546 (2007).
Gooderham, M. J., Van Voorhees, A. S. & Lebwohl, M. G. An update on generalized pustular psoriasis. Expert Rev. Clin. Immunol. 15, 907–919 (2019).
Bissonnette, R. et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J. Dermatol. Sci. 85, 20–26 (2017).
Twelves, S. et al. Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 143, 1021–1026 (2019).
Bangale-Daflapurkar, S. & Danve, A. Pustular psoriasis of pregnancy successfully treated with cyclosporine. Am. J. Ther. 23, e1250–e1252 (2016).
Owczarczyk-Saczonek, A., Znajewska-Pander, A., Owczarek, W., Maciejewska-Radomska, A. & Placek, W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat. 27, 215–219 (2018).
Huang, Y. W. & Tsai, T. F. Juvenile-onset pustular psoriasis: case series and literature review. Br. J. Dermatol. 182, 816–817 (2020).
Sanchez, N. P., Perry, H. O., Muller, S. A. & Winkelmann, R. K. Subcorneal pustular dermatosis and pustular psoriasis. A clinicopathologic correlation. Arch. Dermatol. 119, 715–721 (1983).
Zhu, T., Jin, H., Shu, D., Li, F. & Wu, C. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur. J. Dermatol. 28, 217–224 (2018).
Choon, S. E. et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J. Dermatol. 53, 676–684 (2014).
Navarini, A. A. et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1792–1799 (2017).
Johnston, A. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 140, 109–120 (2017).
Liang, Y., Sarkar, M. K., Tsoi, L. C. & Gudjonsson, J. E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 49, 1–8 (2017).
Griffiths, C. E. & Barker, J. N. Pathogenesis and clinical features of psoriasis. Lancet 370, 263–271 (2007).
Li, M. et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J. Invest. Dermatol. 133, 2637–2639 (2013).
Lohr, S. et al. Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients. Br. J. Dermatol. 175, 639–641 (2016).
Asumalahti, K. et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J. Invest. Dermatol. 120, 627–632 (2003).
Borges-Costa, J. et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am. J. Clin. Dermatol. 12, 271–276 (2011).
Griffiths, C., Barker, J., Chalmers, R., Bleiker, T. & Creamer, D. Rook’s Textbook of Dermatology (John Wiley & Sons, Incorporated, Hoboken, 2016).
Feldmeyer, L., Heidemeyer, K. & Yawalkar, N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int. J. Mol. Sci. 17, 1214 (2016).
Baker, H. & Ryan, T. J. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 80, 771–793 (1968).
Ryan, T. J. & Baker, H. The prognosis of generalized pustular psoriasis. Br. J. Dermatol. 85, 407–411 (1971).
Zelickson, B. D. & Muller, S. A. Generalized pustular psoriasis. A review of 63 cases. Arch. Dermatol. 127, 1339–1345 (1991).
Armstrong, A. W. Psoriasis. JAMA Dermatol. 153, 956 (2017).
Jin, H. et al. Clinical features and course of generalized pustular psoriasis in Korea. J. Dermatol. 42, 674–678 (2015).
Larsabal M. et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br. J. Dermatol. 180, 647–656 (2019).
Yan, D., Afifi, L., Jeon, C., Cordoro, K. M. & Liao, W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol. Online J. 24, 4 (2018).
Ohkawara, A. et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm. Venereol. 76, 68–71 (1996).
Augey, F., Renaudier, P. & Nicolas, J. F. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur. J. Dermatol. 16, 669–673 (2006).
Kharawala, S., Golembesky, A. K., Bohn, R. L. & Esser, D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev. Clin. Immunol. 16, 239–252 (2020).
Trattner, H. et al. Quality of life and comorbidities in palmoplantar pustulosis—a cross-sectional study on 102 patients. J. Eur. Acad. Dermatol. Venereol. 31, 1681–1685 (2017).
Kozlowska, D. et al. Serum sphingolipid level in psoriatic patients with obesity. Postepy Dermatol. Alergol. 36, 714–721 (2019).
Goolam Mahyoodeen, N., Crowther, N. J., Snyman, T., Pillay, L. & Tikly, M. High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis. Int J. Dermatol. 58, 557–562 (2019).
Namiki, K. et al. Thyroid dysfunction in patients with psoriasis: higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis. J. Dermatol. 47, 133–139 (2020).
Xu, W., Li, C. & Zhang, W. The coexistence of SAPHO syndrome and rheumatoid arthritis: a case report. Medicine 96, e5724 (2017).
Rozin, A. P. & Nahir, A. M. Is SAPHO syndrome a target for antibiotic therapy? Clin. Rheumatol. 26, 817–820 (2007).
Ozturk, G. et al. Generalized pustular eruptions due to terbinafine. Cutan. Ocul. Toxicol. 31, 81–84 (2012).
Gammoudi, R. et al. Acute generalized exanthematous pustulosis induced by oxacillin confirmed by patch testing. Contact Dermat. 79, 108–110 (2018).
Webster, G. F. Pustular drug reactions. Clin. Dermatol. 11, 541–543 (1993).
Saeki, H. et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J. Dermatol. 35, 601–603 (2008).
Vasconcellos, J. B. et al. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. Bras. Dermatol. 91, 137–139 (2016).
Jiyad, Z., Moriarty, B., Creamer, D. & Higgins, E. Generalized pustular psoriasis associated with Epstein-Barr virus. Clin. Exp. Dermatol. 40, 146–148 (2015).
Yoneda, K., Matsuoka-Shirahige, Y., Demitsu, T. & Kubota, Y. Pustular psoriasis precipitated by cytomegalovirus infection. Br. J. Dermatol. 167, 1186–1189 (2012).
Pouessel, G. et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr. Dermatol. 24, 401–404 (2007).
Miot, H. A., Miot, L. D., Lopes, P. S., Haddad, G. R. & Marques, S. A. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J. Eur. Acad. Dermatol. Venereol. 23, 1173–1177 (2009).
Wilsmann-Theis, D. et al. Palmoplantar pustulosis—a cross-sectional analysis in Germany. Dermatol. Online J. 23 (2017).
Michaelsson, G., Gustafsson, K. & Hagforsen, E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J. Am. Acad. Dermatol. 54, 737–738 (2006).
Onoufriadis, A. et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89, 432–437 (2011).
Boutet, M. A. et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol. 184, 159–173 (2016).
Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426–2437 (2009).
Bachelez, H. et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med. 380, 981–983 (2019).
McDermott, M. F. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133–144 (1999).
Brydges, S. & Kastner, D. L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 305, 127–160 (2006).
Jesus, A. A. et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheumatol. 63, 4007–4017 (2011).
Minkis, K. et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch. Dermatol. 148, 747–752 (2012).
Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620–628 (2011).
Tauber, M. et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J. Invest. Dermatol. 136, 1811–1819 (2016).
Setta-Kaffetzi, N. et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J. Invest. Dermatol. 133, 1366–1369 (2013).
Mossner, R. et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J. Invest. Dermatol. 135, 2538–2541 (2015).
Takahashi, T., Fujimoto, N., Kabuto, M., Nakanishi, T. & Tanaka, T. Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis. J. Dermatol. 44, 80–83 (2017).
Xiaoling, Y., Dan, S. & Hongzhong, J. Lack of association between mutation in IL36RN and palmoplantar pustular psoriasis in Chinese patients. Bras. Dermatol 94, 658–663 (2019).
Capon, F. IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg? J. Invest. Dermatol. 133, 2503–2504 (2013).
Traks, T. et al. Polymorphisms in IL36G gene are associated with plaque psoriasis. BMC Med. Genet. 20, 10 (2019).
Jordan, C. T. et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784–795 (2012).
Tomfohrde, J. et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264, 1141–1145 (1994).
Blonska, M. & Lin, X. CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol. Rev. 228, 199–211 (2009).
Howes, A. et al. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation. Biochem J. 473, 1759–1768 (2016).
Jordan, C. T. et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am. J. Hum. Genet. 90, 796–808 (2012).
Wang, M. et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity 49, 66–79 (2018).
Fu, F. et al. Rare CARD14 missense variants associated with palmoplantar pustulosis (PPP) in the Chinese Han population. Eur. J. Dermatol. 29, 99–100 (2019).
Tsoi, L. C. et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44, 1341–1348 (2012).
Setta-Kaffetzi, N. et al. AP1S3 mutations are associated with pustular psoriasis and impaired toll-like receptor 3 trafficking. Am. J. Hum. Genet. 94, 790–797 (2014).
Robinson, M. S. Adaptable adaptors for coated vesicles. Trends Cell Biol. 14, 167–174 (2004).
Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732–738 (2001).
Mahil, S. K. et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J. Invest. Dermatol. 136, 2251–2259 (2016).
Frey, S. et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J. Invest. Dermatol. 140, 1451–1455 (2020).
Beatty, K., Bieth, J. & Travis, J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J. Biol. Chem. 255, 3931–3934 (1980).
Henry, C. M. et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 14, 708–722 (2016).
Zhang, Z. & Xu, J. H. Investigation of psoriasis susceptibility loci in psoriatic arthritis and a generalized pustular psoriasis cohort. J. Investig. Dermatol. Symp. Proc. 19, S83–S85 (2018).
Heyninck, K., Kreike, M. M. & Beyaert, R. Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett. 536, 135–140 (2003).
Han, J. W. et al. Tumor necrosis factor-alpha induced protein 3 interacting protein 1 gene polymorphisms and pustular psoriasis in Chinese Han population. Chin. Med. J. 129, 1519–1524 (2016).
Nograles, K. E. et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159, 1092–1102 (2008).
Huffmeier, U., Watzold, M., Mohr, J., Schon, M. P. & Mossner, R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br. J. Dermatol. 170, 202–204 (2014).
Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594–42602 (2011).
Debets, R. et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167, 1440–1446 (2001).
He, Y., Hara, H. & Nunez, G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41, 1012–1021 (2016).
Johnston, A. et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186, 2613–2622 (2011).
Ainscough, J. S. et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma. Proc. Natl Acad. Sci. USA 114, E2748–E2757 (2017).
Clancy, D. M., Henry, C. M., Sullivan, G. P. & Martin, S. J. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J. 284, 1712–1725 (2017).
Liang, Y. et al. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J. Allergy Clin. Immunol. 139, 1217–1227 (2017).
Vigne, S. et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 118, 5813–5823 (2011).
Mutamba, S., Allison, A., Mahida, Y., Barrow, P. & Foster, N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 42, 607–617 (2012).
Arakawa, A. et al. Unopposed IL-36 activity promotes clonal CD4(+) T-cell responses with IL-17A production in generalized pustular psoriasis. J. Invest. Dermatol. 138, 1338–1347 (2018).
Benoit, S., Toksoy, A., Brocker, E. B., Gillitzer, R. & Goebeler, M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br. J. Dermatol. 150, 1009–1012 (2004).
Imafuku, S. et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J. Dermatol. 43, 1011–1017 (2016).
Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204, 2603–2614 (2007).
Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131, 2428–2437 (2011).
Robinson, A. et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 67, 279–288 (2012).
Torii, H., Nakagawa, H. & Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J. Dermatol. 38, 321–334 (2011).
Kimura, U. et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J. Dermatol. 39, 286–287 (2012).
Wendling, D. et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Jt. Bone Spine 75, 315–318 (2008).
Arakawa, A., Ruzicka, T. & Prinz, J. C. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 152, 825–828 (2016).
Bissonnette, R. et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 28, 1298–1305 (2014).
Husson, B. et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J. Eur. Acad. Dermatol. Venereol. https://doi.org/10.1111/jdv.16265 (2020).
Mrowietz, U. et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J. Am. Acad. Dermatol. 80, 1344–1352 (2019).
Mansouri, B., Richards, L. & Menter, A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br. J. Dermatol. 173, 239–241 (2015).
Skendros, P. et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br. J. Dermatol. 176, 212–215 (2017).
Mansouri, B., Kivelevitch, D., Campa, M. & Menter, A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1beta antagonist canakinumab. Clin. Exp. Dermatol. 41, 324–326 (2016).
Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H. & Elder, J. T. Mouse models of psoriasis. J. Invest. Dermatol. 127, 1292–1308 (2007).
Campbell, J. J. et al. Efficacy of chemokine receptor inhibition in treating IL-36alpha-induced psoriasiform inflammation. J. Immunol. 202, 1687–1692 (2019).
Foster, A. M. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053–6061 (2014).
Hawkes, J. E., Gudjonsson, J. E. & Ward, N. L. The snowballing literature on imiquimod-induced skin inflammation in mice: a critical appraisal. J. Invest. Dermatol. 137, 546–549 (2017).
Alvarez, P. & Jensen, L. E. Imiquimod treatment causes systemic disease in mice resembling generalized pustular psoriasis in an IL-1 and IL-36 dependent manner. Mediators Inflamm. 2016, 6756138 (2016).
Shao, S. et al. Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front. Immunol. 10, 746 (2019).
Sundberg, J. P. et al. Gain of function p.E138A alteration in Card14 leads to psoriasiform skin inflammation and implicates genetic modifiers in disease severity. Exp. Mol. Pathol. 110, 104286 (2019).
Swindell, W. R. et al. RNA-Seq Analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature. Front. Immunol. 9, 80 (2018).
Trivedi, M. K., Vaughn, A. R. & Murase, J. E. Pustular psoriasis of pregnancy: current perspectives. Int J. Women’s Health 10, 109–115 (2018).
Ross, M. G., Tucker, D. C. & Hayashi, R. H. Impetigo herpetiformis as a cause of postpartum fever. Obstet. Gynecol. 64, 49S–51S (1984).
Yamashita, T. et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. Int J. Dermatol. 58, 350–353 (2019).
Tay, Y. K. & Tham, S. N. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J. Dermatol. 36, 266–271 (1997).
Xiao, T., Li, B., He, C. D. & Chen, H. D. Juvenile generalized pustular psoriasis. J. Dermatol. 34, 573–576 (2007).
Wang, Q., Liu, W. & Zhang, L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China. Bras. Dermatol. 92, 319–322 (2017).
de Oliveira, S. T., Maragno, L., Arnone, M., Fonseca Takahashi, M. D. & Romiti, R. Generalized pustular psoriasis in childhood. Pediatr. Dermatol. 27, 349–354 (2010).
Korber, A. et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J. Invest. Dermatol. 133, 2634–2637 (2013).
Sugiura, K. et al. A novel IL36RN/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult-onset generalized pustular psoriasis. Br. J. Dermatol. 167, 699–701 (2012).
Farooq, M. et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum. Mutat. 34, 176–183 (2013).
Li, M. et al. IL36RN gene mutations are not associated with sporadic generalized pustular psoriasis in Chinese patients. Br. J. Dermatol. 168, 452–455 (2013).
Hussain, S. et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J. Allergy Clin. Immunol. 135, 1067–1070. e1069 (2015).
Ammar, M. et al. CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. Br. J. Dermatol. 174, 330–337 (2016).
Mossner, R. et al. The genetic basis for most patients with pustular skin disease remains elusive. Br. J. Dermatol. 178, 740–748 (2018).
Sugiura, K., Muto, M. & Akiyama, M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J. Invest. Dermatol. 134, 1755–1757 (2014).
Tobita, R. et al. A novel CARD14 variant, homozygous c.526G>C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis. Clin. Exp. Dermatol. 44, 694–696 (2019).
Qin, P. et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis. J. Invest. Dermatol. 134, 2994–2996 (2014).
Tauber, M. et al. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br. J. Dermatol. 171, 646–649 (2014).
ClinicalTrialNCT03886246. A 5-year study to test BI 655130 in patients with generalized pustular psoriasis who took part in previous studies with BI 655130. Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03886246 (2019).
ClinicalTrialNCT03135548. Initial dosing of BI 655130 in palmoplantar pustulosis patients. Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03135548 (2019).
ClinicalTrialNCT03619902. A study to evaluate the efficacy and safety of ANB019 in subjects with generalized pustular psoriasis (GPP). Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03619902 (2019).
ClinicalTrialNCT03633396. A study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis (PPP). Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03633396 (2019).
This work was supported by the Babcock Endowment Fund (L.C.T. and J.E.G.), the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award numbers R01-AR060802 (J.E.G.), P30-AR075043 (J.E.G.), and K01-AR072129 (L.C.T.), and the National Institute of Allergy and Infectious Diseases under award number R01-AR069071 (J.E.G.), the A. Alfred Taubman Medical Research Institute (J.E.G. and J.M.K.), the National Psoriasis Foundation (J.E.G, N.L.W., J.M.K., E.M., and L.C.T.), and the Parfait Emerging Scholar Award (J.M.K.). L.C.T. is supported by the Dermatology Foundation, the Arthritis National Research Foundation, and the National Psoriasis Foundation.
The authors declare no competing interests.
About this article
Cite this article
Uppala, R., Tsoi, L.C., Harms, P.W. et al. “Autoinflammatory psoriasis”—genetics and biology of pustular psoriasis. Cell Mol Immunol 18, 307–317 (2021). https://doi.org/10.1038/s41423-020-0519-3
This article is cited by
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis
British Journal of Cancer (2023)
Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis
Nature Communications (2023)
Journal of Nanobiotechnology (2022)
IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist
American Journal of Clinical Dermatology (2022)